0000921895-17-000056.txt : 20170113
0000921895-17-000056.hdr.sgml : 20170113
20170113180026
ACCESSION NUMBER: 0000921895-17-000056
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170111
FILED AS OF DATE: 20170113
DATE AS OF CHANGE: 20170113
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CTI BIOPHARMA CORP
CENTRAL INDEX KEY: 0000891293
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 911533912
STATE OF INCORPORATION: WA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3101 WESTERN AVENUE
STREET 2: SUITE 600
CITY: SEATTLE
STATE: WA
ZIP: 98121
BUSINESS PHONE: 2062827100
MAIL ADDRESS:
STREET 1: 3101 WESTERN AVENUE
STREET 2: SUITE 600
CITY: SEATTLE
STATE: WA
ZIP: 98121
FORMER COMPANY:
FORMER CONFORMED NAME: CELL THERAPEUTICS INC
DATE OF NAME CHANGE: 19960321
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PERRY MATTHEW D
CENTRAL INDEX KEY: 0001454337
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-28386
FILM NUMBER: 17528784
MAIL ADDRESS:
STREET 1: ONE SANSOME STREET
STREET 2: 30TH FLOOR
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
4
1
form407422010_01132017.xml
OWNERSHIP DOCUMENT
X0306
4
2017-01-11
0
0000891293
CTI BIOPHARMA CORP
CTI
0001454337
PERRY MATTHEW D
ONE SANSOME STREET
30TH FLOOR
SAN FRANCISCO
CA
94104
1
0
0
1
See Explanation of Responses
Common Stock
2017-01-11
4
M
0
8403
A
8403
D
Restricted Stock Units
2017-01-11
4
M
0
8403
0.00
D
Common Stock
0
0
D
Restricted Stock Units
Common Stock
34736
34736
D
The Reporting Person may be deemed to be a member of a Section 13(d) group that may be deemed to collectively beneficially own more than 10% of the Issuer's outstanding shares of Common Stock.
Each restricted stock unit represents the right to receive, at settlement, one share of CTIC common stock. On December 9, 2016, the Issuer announced that the Board of Directors of the Issuer (the "Board") approved a reverse stock split in order to regain compliance with certain NASDAQ requirements. Upon the effectiveness of the reverse stock split, each of the Issuer's shareholders received one new share of the Issuer's Common Stock for every ten shares of the Common Stock that such shareholder held (the "Reverse Stock Split"). As such, pursuant to the Reverse Stock Split, the 347,360 restricted stock units ("RSUs") and corresponding right to receive 347,360 shares of Common Stock, and 84,034 RSUs and corresponding right to receive 84,034 shares of Common Stock, as previously reported, became 34,736 RSUs and corresponding right to receive 34,736 shares of Common Stock, and 8,403 RSUs and corresponding right to receive 8,403 shares of Common Stock, respectively.
These restricted stock units were scheduled to vest on the first to occur of (i) the date that is twelve months after the date of grant, (ii) the first annual meeting of CTIC's shareholders in 2017 at which one or more members of the Board are to be elected, or (iii) immediately prior to the occurrence of a Change of Control (as such term is defined in CTIC's 2015 Equity Incentive Plan), subject to the Reporting Person's continued service through such date or event.
This restricted stock unit was granted on April 29, 2016 and scheduled to vest twelve months after grant date or, if earlier, the first annual meeting of CTIC's shareholders in 2017 at which one or more members of the Board are to be elected.
/s/ Matthew D. Perry
2017-01-13